Last reviewed · How we verify
Minocyclin
At a glance
| Generic name | Minocyclin |
|---|---|
| Also known as | Minocycline HCL 200mg Daily (Oral or Intravenous) |
| Sponsor | University of Southern California |
| Target | 30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Acne vulgaris
- Actinomycotic infection
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Anthrax
- Bartonellosis
- Bronchitis
- Brucellosis
- Chancroid
- Chlamydia trachomatis infection of genital structure
- Cholera
- Fusospirochetal pharyngitis
- Gingivostomatitis
- Gonorrhea
- Gonorrhea of pharynx
- Gonorrhea of rectum
- Granuloma inguinale
- Inclusion conjunctivitis
- Infection by Campylobacter fetus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Dyspepsia
- Anorexia
- Headache
- Dizziness
- Vertigo
- Rash
- Pruritus
- Maculopapular rash
- Erythematous rash
Serious adverse events
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Anaphylaxis/anaphylactoid reaction
- Fatal hepatic failure
- Pseudotumor cerebri (benign intracranial hypertension)
- Reversible acute renal failure
- Thyroid cancer
- Hypersensitivity syndrome
- Lupus-like syndrome
- Pneumonitis
Key clinical trials
- Minocycline as Adjunctive Treatment for Treatment Resistant Depression (PHASE3)
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Minocycline in Stroke Study at Maimonides (PHASE2, PHASE3)
- Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment (NA)
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Topical Minocycline for CARP (EARLY_PHASE1)
- Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke (PHASE2)
- Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |